#	Pagina
attuale pagina	/open-h2020/projects/198858/index.html

Opendata, web and dolomites

EPICHECK

Detection of Various Cancer Types for Screening and Diagnosis through Blood Samples with Epigenetic Biomarkers Panels

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

EPICHECK project word cloud

Explore the words cloud of the EPICHECK project. It provides you a very rough idea of what is the project "EPICHECK" about.

patients epigenetic 5th recurrence 07 monitoring stools 23 body 126 epicheck subject expertise comprising marker invasive 320m methylation 15 urine extracted screening disease diagnosed company world overlapping sensitive markers panels blood commercial diagnosis fluids revenues million revolutionary billion sensitivity accurate q4 individuals nucleix plans owned people gdp cancer 2015 45m detection sputum health sick lung proof kits launched first initially bladder specificity distinguish identification public extremely panel surveillance dna 2008 bio loci proven colorectal locations multiplex applicable diagnostic died platform generate rate translate identifies healthy 2009 tight samples

Project "EPICHECK" data sheet

The following table provides information about the project.

Coordinator	NUCLEIX LTD Organization address address: 3 PEKERIS STREET city: REHOVOT postcode: 7670203 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Israel [IL]
Project website	http://www.nucleix.com
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2015
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-10-01 to 2016-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	NUCLEIX LTD NUCLEIX LTD Organization address address: 3 PEKERIS STREET city: REHOVOT postcode: 7670203 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IL (REHOVOT)	coordinator	50˙000.00

Map

Project objective

Nucleix developed a revolutionary platform for the development of Methylation Bio-markers and Bio-Marker panels for screening (early detection of disease) and diagnosis based on epigenetic markers. The platform identifies changes in specific methylation locations of DNA extracted from body fluids such as – urine, blood, stools and sputum. A Bio-Markers panel goal is to distinguish between sick and healthy individuals. The company’s expertise include the identification of the specific loci, comprising a panel of markers that can work in multiplex and generate highly accurate test. Nucleix technology was proven to be extremely sensitive and specific in its first application. Nucleix focuses initially on the field of cancer detection and screening. Cancer cost the EU €126 billion in 2009, which was 1.07% of EU GDP. 2.45m People in the EU were diagnosed with cancer in 2008, when 1.23 million people in the EU died from cancer in 2008. This is one of the most significant public health issues in the world and in the EU. Nucleix first product, Bladder EpiCheck is a urine test for the detection of Bladder Cancer. It is aimed for monitoring bladder cancer patients as this is a disease with high recurrence rate and requires tight surveillance. This product will be launched in Q4 of 2015. The test is based on a panel of 15 non-overlapping Methylation markers at loci that were identified, developed and owned by the company. This product which has better sensitivity and specificity than any other non-invasive test is a proof of the company’s ability to translate its technology to applicable products. The company plans to develop EPICHECK - diagnostic kits using multi-loci panel of markers, for the detection and screening of lung cancer and colorectal cancer in blood samples – which is the subject of this applications. EPICHECK will be launched rapidly, and will provide revenues of over 320m Euro in its 5th year of commercial activities.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPICHECK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPICHECK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development